Physicians' Academy for Cardiovascular Education

Total mortality, but not sudden cardiac death, lower by wearable cardioverter-defibrillator in the immediate post-MI period with low EF

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL. USA - Jeffrey Olgin (San Francisco, CA, USA

ACC 2018 The randomised VEST trial examined whether a wearable defibrillator in the first three months after MI in patients with LVEF <35% lowered the early mortality risk.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.


Jeffrey Olgin, MD is a cardiologist and electrophysiologist at UCSF Medical Center in San Francisco, CA, USA.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Read more about the results of the VEST trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: